S355
Clinical - CNS
ESTRO 2026
for prospective investigations. Keywords: Visual toxicity, optic neuropathy, proton
Proffered Paper 423 Dual Inhibition of Post-Radiogenic Revascularization in Newly-Diagnosed Glioblastoma - Final results of the multicentric phase 1/2 GLORIA trial. Julian P. Layer 1,2 , Clemens Seidel 3 , Lea L. Friker 4,2 , Roberta Turiello 2 , Anna-Laura Potthoff 5 , Oriol Mirallas 6 , Thomas Zeyen 7 , Peter Hambsch 3 , Sied Kebir 8 , Mirjam Renovanz 9 , Torsten Pietsch 4 , Matthias Schneider 5 , Michael Platten 10,11 , Eleni Gkika 1 , Oliver Grauer 12 , Ghazaleh Tabatabai 9 , Martin Glas 8 , Ulrich Herrlinger 7 , Michael Hölzel 2 , Frank A. Giordano 13,14 1 Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany. 2 Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. 3 Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany. 4 Institute of Neuropathology, University Hospital Bonn, Bonn, Germany. 5 Department of Neurosurgery, University Hospital Bonn, Bonn, Germany. 6 Medical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology, Barcelona, Spain. 7 Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany. 8 Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C- TNBS), Division of Clinical Neuro-Oncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany. 9 Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany. 10 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. 11 DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany. 12 Department of Neurology with Institute of Translation Neurology, University Hospital Muenster, Muenster, Germany. 13 Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. 14 DKFZ-Hector Cancer Institute, German Cancer Research Center, Mannheim, Germany Purpose/Objective: Despite maximum safe resection followed by radiochemotherapy, glioblastoma (GBM) remains associated with a severely limited prognosis. Rapid vascular recovery is a key feature preceding recurrence after radiotherapy (RT). Despite prolonging progression-free survival (PFS) in prior phase 3 trials, VEGF-targeted angiogenesis inhibition failed to translate into an overall survival (OS) benefit,
Figure 2: Forest plots demonstrating subgroup analysis on treatment type and the prevalence RION across individual studies along with the pooled estimate.
Conclusion: RION occurs in approximately 5% of patients after proton therapy. The comparatively elevated risk associated with proton therapy underscores the need
Made with FlippingBook - Share PDF online